Effect of Continuous Renal Replacement Therapy on Mortality in the Intensive Care Unit: A Retrospective Analysis

Yıl 2024, Cilt: 21 Sayı: 2, 220 - 227

Metin Yıldız Evren Büyükfırat Ahmet Atlas Mahmut Alp Karahan Nuray Altay

https://doi.org/10.35440/hutfd.1493571

Öz

Background: In this study, we aimed to retrospectively evaluate the demographic data, clinical diagnoses, laboratory values and scoring systems that may be effective in predicting mortality in patients undergoing continuous renal replacement therapy (CRRT) in our intensive care unit.
Materials and Methods: The data of patients who underwent CRRT in our tertiary intensive care unit were retrospectively analyzed. Digital archive data of Intensive Care Units, patients' medical history, laboratory results and nurse observation forms were analyzed. Acute Physiology and Chronic Health Evaluation II (APACHE II), Glasgow Coma score (GCS), Sequential Organ Failure Assessment (SOFA), Crp/Albumin ratio were analyzed at four time points (during ICU admission, before CRRT, after CRRT and discharge) and their effects on mortality were compared.
Results: A total of 107 patients were included in our study between 2017 and 2022 and 101 of these cases resulted in mortality. The change in CRP/Albumin values and GCS scores after CRRT compared to before CRRT was not significant (p>0.05), but the decrease in APACHE II (p<0.01) and SOFA (p<0.01) scores were found to be significant in predicting mortality. No significant difference was found in terms of gender and body mass index measurements, use of inotropic agents, length of intensive care unit stay, length of hospital stay and comorbidities (p>0.05). However, age was found to be a risk factor for mortality (p<0.01).
Conclusion: Although CRRT is performed in intensive care unit patients for many underlying causes and can improve APACHE II and SOFA scores, no statistically significant relationship was found be-tween CRP/Albumin ratio in predicting the effect of CRRT on mortality

Anahtar Kelimeler

Continuous renal replacement therapy, acute kidney injury, intensive care unit

Yoğun Bakım Ünitesinde Uygulanan Sürekli Renal Replasman Tedavisinin Mortalite üzerine Etkisi: Retrospektif Analiz

Öz

Amaç: Bu çalışmada yoğun bakım ünitemizde sürekli renal replasman tedavisi (SRRT) uygulanan hastaların demografik verilerini, klinik tanılarını ve mortaliteyi öngörmede etkili olabilecek labora-tuvar değerlerini ve skorlama sistemlerini retrospektif olarak değerlendirmeyi amaçladık.
Materyal ve Metod: Üçüncü basamak yoğun bakım ünitemizde SRRT uygulanan hastaların verileri retrospektif olarak incelendi. Yoğun Bakım Üniteleri‘ne ait dijital arşiv verileri, hastaların doktor anamnezi, laboratuvar sonuçları ve hemşire gözlem formları incelendi. Hastalara dört zaman dili-minde (yoğun bakım yatışında, SRRT öncesinde, SRRT sonrası ve taburculuk) Acute Physiology and Chronic Health Evaluation II (APACHE II), Glaskow Koma skoru (GKS), Sequential Organ Failure As-sessment (SOFA), Crp/Albümin oranı incelenip, mortaliteye olan etkileri karşılaştırıldı.
Bulgular: Çalışmamıza 2017-2022 yılları arasında toplam 107 hasta dahil edildi ve bu olguların 101’i mortalite ile sonuçlanmıştır. SRRT öncesine göre SRRT sonrası CRP/Albümin değerlerinde ve GKS skorlarında değişim anlamlı bulunmamış (p>0,05), ancak APACHE II (p<0,01), ve SOFA (p<0,01) skorla-rındaki düşüşün ise mortaliteyi öngörmede anlamlı bulunmuştur. Mortaliteye göre olguların cinsiye-ti ve vücut kitle indeksi ölçümleri, inotropik ajan kullanımı, yoğun bakımda yatış süresi, hastanede kalış süresi ve ek hastalık açısından anlamlı fark bulunmadı (p>0,05). Ancak yaşın mortalite açısından risk faktörü olduğu saptandı (p<0,01).
Sonuç: SRRT yoğun bakım hastalarında birçok altta yatan sebep nedeniyle uygulanmakta, APACHE II ve SOFA skorlarını iyileştirebilmekle beraber; CRP/Albümin değerinin SRRT işleminin mortalite üzerindeki etkisini öngörmede istatiksel olarak anlamlı bir ilişki bulunamamıştır.

Anahtar Kelimeler

Sürekli renal replasman tedavisi, akut böbrek hasarı, yoğun bakım

Etik Beyan

This study was planned retrospectively and the approval of XXX University Clinical Research Ethics Committee (decision dated 08.08.2022 and numbered 2022/15/05) was obtained before the study.

Kaynakça

• 1. Boyacı Dündar NB. Yoğun Bakımda Renal Replasman Tedavileri ve Uygulama İlkeleri. In: Altıntaş ND, Özyılmaz E, Ferliçolak L, Editors. Temel Yoğun Bakım Kitabı. Ankara: Bayt; 2022; 85-90.
• 2. Braig D, Nero TL, Koch HG, Kaiser B, Wang X, Thiele JR, et al. Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites. Nat Commun. 2017;8:14188.
• 3. Devran O, Karakurt Z, Adıgüzel N, Güngör G, Moçin OY, Balcı MK, et al. C-reactive protein as a predictor of morta-lity in patients affected with severe sepsis in intensive ca-re unit. Multidiscip Respir Med. 2012;7(1):47.
• 4. Kim MH, Ahn JY, Song JE, Choi H, Ann HW, Kim JK, et al. The C-Reactive Protein/Albumin Ratio as an Independent Predictor of Mortality in Patients with Severe Sepsis or Septic Shock Treated with Early Goal-Directed Therapy. PLoS One. 2015;10(7):e0132109.
• 5. Oh TK, Song IA, Lee JH. Clinical usefulness of C-reactive protein to albumin ratio in predicting 30-day mortality in critically ill patients: A retrospective analysis. Sci Rep. 2018;8(1):14977.
• 6. Medina-Liabres KRP, Jeong JC, Oh HJ, An JN, Lee JP, Kim DK, et al. Mortality predictors in critically ill patients with acute kidney injury requiring continuous renal replace-ment therapy. Kidney Res Clin Pract. 2021;40(3):401–10.
• 7. Gjyzari A, Muzi L, Morabito S. Continuous Renal Replace-ment Therapy for Acute Renal Failure in Critically Ill Pati-ents and Early Predictive Factors. BANTAO J. 2007;5(2):58–60.
• 8. Hoste EAJ, Bagshaw SM, Bellomo R, Cely CM, Colman R, Cruz DN, et al. Epidemiology of acute kidney injury in criti-cally ill patients: the multinational AKI-EPI study. Intensive Care Med [Internet]. 2015;41(8):1411–23.
• 9. Tatum JM, Barmparas G, Ko A, Dhillon N, Smith E, Margu-lies DR, et al. Analysis of Survival After Initiation of Conti-nuous Renal Replacement Therapy in a Surgical Intensive Care Unit. JAMA Surg. 2017;152(10):938–43.
• 10. Wang H, Kang X, Shi Y, Bai ZH, Lv JH, Sun JL, et al. SOFA score is superior to APACHE-II score in predicting the prognosis of critically ill patients with acute kidney injury undergoing continuous renal replacement therapy. Ren Fail. 2020;42(1):638–45.
• 11. Katayama S, Uchino S, Uji M, Ohnuma T, Namba Y, Kawarazaki H, et al. Factors predicting successful discon-tinuation of continuous renal replacement therapy. Ana-esth Intensive Care. 2016;44(4):453–7.
• 12. RENAL Replacement Therapy Study Investigators, Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, et al. Intensity of continuous renal-replacement therapy in critically ill pati-ents. N Engl J Med. 2009;361(17):1627–38.
• 13. Claure-Del Granado R, Macedo E, Chertow GM, Soroko S, Himmelfarb J, Ikizler TA, et al. Effluent volume in conti-nuous renal replacement therapy overestimates the deli-vered dose of dialysis. Clin J Am Soc Nephrol. 2011;6(3):467–75.
• 14. Goldhill DR, Sumner A. Outcome of intensive care pati-ents in a group of British intensive care units. Crit Care Med [Internet]. 1998;26(8):1337–45.
• 15. Oruc A, Ersoy A, Hoyrazli A, Altinay T, Aktas N, Yildiz A, et al. Should Hemodialysis for Renal Replacement Treat-ment in Hospitalized Patients with Acute Kidney Injury be Intermittent or Continous. Turkish Nephrol Dial Transplant [Internet]. 2012;21(01):72–7.
• 16. Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt H, et al. Effect of Early vs Delayed Initiation of Renal Replacement Therapy on Mortality in Critically Ill Patients With Acute Kidney Injury: The ELAIN Randomized Clinical Trial. JAMA. 315(20):2190–9.
• 17. Park JE, Chung KS, Song JH, Kim SY, Kim EY, Jung JY, et al. The C-Reactive Protein/Albumin Ratio as a Predictor of Mortality in Critically Ill Patients. J Clin Med. 2018; 7(10):333.
• 18. Karagoz I, Ozer B, Ital I, Turkoglu M, Disikirik A, Ozer S. C-reactive protein-to-serum albumin ratio as a marker of prognosis in adult intensive care population. Bratisl Lek Listy. 2023;124(4):277–9.
• 19. Özdemir İH, Özlek B, Özen MB, Gündüz R, Çetin N, Özlek E, et al. Prognostic value of C-reactive protein/albumin ra-tio in hypertensive COVID-19 patients. Clin Exp Hypertens. 2021;43(7):683–9.
• 20. Saylik F, Akbulut T, Kaya S. Can C-Reactive Protein to Albumin Ratio Predict In-Hospital Death Rate Due to COVID-19 in Patients With Hypertension? Angiology. 2021;72(10):947–52.